At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 119 enrolled
Drug / intervention
BMS-936558 (Anti-PD-1) +2 moredrug
Likely dose
BMS-936558 (Anti-PD-1) 0.3 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Exploratory Study to Investigate the Immunomodulatory Activity of Various Dose Levels of Anti Programmed-Death-1 (PD-1) Antibody (BMS-936558) in Subjects With Metastatic Clear Cell Renal Cell Carcinoma (RCC).
In Brief
A Phase 1 clinical trial evaluating BMS-936558 (Anti-PD-1) for Renal Cell Carcinoma. Completed, enrolled 119 participants across 14 sites in 3 countries.
Detailed Summary
The purpose of this study is to evaluate the pharmacodynamic and biologic properties of BMS-936558 in subjects with metastatic renal cell carcinoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Cell Carcinoma
CountriesFrance, Spain, United States
CollaboratorsOno Pharma USA Inc
Timeline
Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMay 2011
Enrollment StartSep 2011
Primary CompletionDec 2014
Study CompletionMay 2019
TodayJul 2026
First PostedMay 24, 2011
Enrollment StartSep 23, 2011
Primary CompletionDec 1, 2014
Study CompletionMay 22, 2019
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 15.1 years ago
Interventions
BMS-936558 (Anti-PD-1)drug
Solution, Intravenous infusion, 0.3 mg/kg, Every 3 weeks, Indefinitely depending on response
BMS-936558 (Anti-PD-1)drug
Solution, Intravenous infusion, 2 mg/kg, Every 3 weeks, Indefinitely depending on response
BMS-936558 (Anti-PD-1)drug
Solution, Intravenous infusion, 10 mg/kg, Every 3 weeks, Indefinitely depending on response